Regeneron Pharmaceuticals, Inc. Share Price Today: Live Updates & Key Insights

Regeneron Pharmaceuticals, Inc. share price today is $736.44, up -0.62%. The stock opened at $740.255 against the previous close of $737.45, with an intraday high of $744.08 and low of $729.

Regeneron Pharmaceuticals, Inc. Share Price Chart

Regeneron Pharmaceuticals, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Regeneron Pharmaceuticals, Inc. Share Price Performance

$736.44 -0.0062(-0.62%) REGN at 23 Mar 2026 02:59 PM Biotechnology
Lowest Today 729
Highest Today 744.08
Today’s Open 740.255
Prev. Close 737.45
52 Week High 820.12
52 Week Low 474.60
Day’s Range: Low 729 High 744.08
52-Week Range: Low 474.60 High 820.12
1 day return -
1 Week return -3.13
1 month return -6.82
3 month return -5.95
6 month return +23.04
1 year return +10.93
3 year return -2.53
5 year return +51.62
10 year return -

Regeneron Pharmaceuticals, Inc. Institutional Holdings

Vanguard Group Inc 8.58

BlackRock Inc 8.36

JPMorgan Chase & Co 7.70

State Street Corp 4.44

Dodge & Cox 4.35

Vanguard Total Stock Mkt Idx Inv 2.92

Dodge & Cox Stock I 2.83

Vanguard 500 Index Investor 2.43

Geode Capital Management, LLC 2.38

Franklin Resources Inc 2.32

FMR Inc 2.19

Invesco QQQ Trust 2.08

Nuveen, LLC 1.90

Loomis, Sayles & Company LP 1.83

Amvescap Plc. 1.40

Morgan Stanley - Brokerage Accounts 1.37

Capital World Investors 1.32

NORGES BANK 1.24

iShares Core S&P 500 ETF 1.22

Fidelity 500 Index 1.21

State Street® SPDR® S&P 500® ETF 1.12

Bank of America Corp 1.09

Putnam Large Cap Value A 1.02

Putnam US Large Cap Value Equity 1.02

AQR Capital Management LLC 0.94

Northern Trust Corp 0.93

The Goldman Sachs Group Inc 0.90

Vanguard Value Index Inv 0.85

T. Rowe Price Associates, Inc. 0.76

Amundi 0.75

iShares Biotechnology ETF 0.72

State Street®HlthCrSelSectSPDR®ETF 0.71

CREF Total Global Stock Account R3 0.60

JPMorgan Equity Premium Income ETF 0.59

American Funds Growth Fund of Amer A 0.57

Capital Group Growth Fnd of Amer Comp 0.57

Vanguard Institutional Index I 0.54

Vanguard Wellington Inv 0.52

State St S&P 500® Indx SL Cl III 0.51

CREF Growth R3 0.50

Regeneron Pharmaceuticals, Inc. Market Status

Strong Buy: 14

Buy: 5

Hold: 5

Sell: 1

Strong Sell: 0

Regeneron Pharmaceuticals, Inc. Fundamentals

Market Cap 77478.88 M

PB Ratio 2.4788

PE Ratio 17.668

Enterprise Value 71579.57 M

Total Assets 40558.70 M

Volume 1359993

Regeneron Pharmaceuticals, Inc. Company Financials

Annual Revenue FY25:14342900000 14342.9M, FY24:14202000000 14202.0M, FY23:13097300000 13097.3M, FY22:12172900000 12172.9M, FY21:16071700000 16071.7M

Annual Profit FY25:12242200000 12242.2M, FY24:12231500000 12231.5M, FY23:11257900000 11257.9M, FY22:10612500000 10612.5M, FY21:13634200000 13634.2M

Annual Net worth FY25:4504900000 4504.9M, FY24:4412600000 4412.6M, FY23:3991100000 3991.1M, FY22:4338400000 4338.4M, FY21:8075300000 8075.3M

Quarterly Revenue Q4/2025:3884300000 3884.3M, Q3/2025:3754300000 3754.3M, Q2/2025:3675600000 3675.6M, Q1/2025:3028700000 3028.7M, Q4/2024:3789200000 3789.2M

Quarterly Profit Q4/2025:3299700000 3299.7M, Q3/2025:3232700000 3232.7M, Q2/2025:3145400000 3145.4M, Q1/2025:2564400000 2564.4M, Q4/2024:3223800000 3223.8M

Quarterly Net worth Q4/2025:844600000 844.6M, Q3/2025:1460000000 1460.0M, Q2/2025:1391600000 1391.6M, Q1/2025:808700000 808.7M, Q4/2024:917700000 917.7M

About Regeneron Pharmaceuticals, Inc. & investment objective

Company Information Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

Organisation Biotechnology

Employees 15410

Industry Biotechnology

CEO Dr. Leonard S. Schleifer M.D., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Regeneron Pharmaceuticals, Inc. FAQs

What is the share price of Regeneron Pharmaceuticals, Inc. today?

The current share price of Regeneron Pharmaceuticals, Inc. is $736.44.

Can I buy Regeneron Pharmaceuticals, Inc. shares in India?

Yes, Indian investors can buy Regeneron Pharmaceuticals, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Regeneron Pharmaceuticals, Inc. shares in India?

You can easily invest in Regeneron Pharmaceuticals, Inc. shares from India by:

Can I buy fractional shares of Regeneron Pharmaceuticals, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. has a market cap of $77478.88 M.

In which sector does Regeneron Pharmaceuticals, Inc. belong?

Regeneron Pharmaceuticals, Inc. operates in the Biotechnology sector.

What documents are required to invest in Regeneron Pharmaceuticals, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Regeneron Pharmaceuticals, Inc.?

The PE ratio of Regeneron Pharmaceuticals, Inc. is 17.67 and the PB ratio is 2.48.